Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCARF: Saxagliptin on Cardiac Structure and Function
NCT02481479Phase 4Completed
- Sponsor
- Unity Health Toronto
- Start
- Jun 2015
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of saxagliptin in type 2 diabetes mellitus (T2DM), sponsored by Unity Health Toronto. Primary endpoint: Left Ventricular Ejection Fraction at 6 months. Started Jun 2015; status: completed.
02
Drugs
saxagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02481479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02481479.